Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.

---

Classification

---

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Neuroscience Mental Health Opioid FDA Multiple Sclerosis Stroke Psychiatry Depressive Disorder Major Depressive Disorder Smoking Neuromodulation Neurotechnology Smoking Cessation Neurophysiology Treatment Of Major Depressive Disorder Fatigue Obsessive Compulsive Disorder Addiction Neuromodulation Products Neuropsychology Post Traumatic Stress Disorder Treatment Of Depression